All articles tagged with #screening guidelines
Lung cancer is increasingly diagnosed in healthy, non-smokers—often younger women—driven by genetic changes like ALK and environmental factors such as air pollution and burn-pit toxins; experts urge expanding screening beyond smoking history and highlight targeted therapies that can turn advanced disease into a manageable condition.
A new American Cancer Society report finds rectal cancer rates are rising across ages and are driving an uptick in colorectal cancer diagnoses among people under 65 in the U.S., with rectal cancers now making up about a third of cases. From 2018–2022, rectal cancer rose about 1% annually in all ages, while younger groups saw faster increases (up to 3% for ages 20–49). The trend is prompting discussion on screening age (USPSTF has lowered it to 45) and faster symptom education/referrals, as many under-50 patients are diagnosed at advanced stages. Emphasized risk factors include smoking, excess weight, physical inactivity, and diet; reducing these could help lower risk.
New American Cancer Society data show nearly half of colorectal cancers now occur in adults under 65, with rising cases in ages 50–64 and a notable increase in rectal cancer, likely reflecting a birth-cohort effect and environmental influences; experts emphasize paying attention to symptoms and that screening for average risk starts at age 45, while treatment varies by stage and may involve surgery, chemotherapy, and radiation for rectal cancer.
The piece explains that colorectal cancer is increasingly affecting younger people, leading to guidelines that now start average-risk screening at age 45 with a colonoscopy every 10 years (or stool tests as alternatives), notes that a family or personal history can trigger earlier testing, and discusses symptoms, costs, and the role of noninvasive tests like Cologuard and FIT. It also highlights that lifestyle factors and access to care influence risk and screening uptake.
Colorectal cancer is rising among people under 50, with possible links to diet, alcohol, smoking, obesity, and gut microbiome imbalances; early warning signs include blood in stool, abdominal pain, and changes in bowel habits, prompting medical evaluation. Screening for average risk typically begins at age 45 (with colonoscopy emphasized for higher risk), while high-risk individuals may need earlier testing. Catching cancer early can yield 80–90% 5-year survival, whereas advanced or metastatic disease has much poorer outcomes. Reducing risk involves regular exercise, a fiber-rich diet with less red/processed meat, maintaining a healthy weight, moderating alcohol and avoiding tobacco, and sharing family history with your clinician to tailor screening and prevention.
An analysis of nearly 1.3 million cancer deaths in Americans under 50 from 1990–2023 shows colorectal cancer is now the leading cancer killer in this group, with deaths increasing about 1% annually since 2005 while overall under-50 cancer deaths have fallen about 44% since 1990. Other top cancers declined, making the colorectal rise an outlier. Possible contributors include obesity, inactivity, diet, and microbiome changes, but the exact cause is unclear. The study underscores the importance of awareness and screening, with USPSTF guidance now recommending universal screening starting at 45 (earlier for high-risk groups), and noting roughly half of under-50 cases occur at ages 45–49.
A American Cancer Society study published in JAMA finds that cancer death rates for people under 50 have dropped 44% from 1990 to 2023, driven by declines in breast cancer, leukemia, and especially lung cancer. However, colorectal cancer deaths in this age group have risen, making CRC the leading cancer killer under 50 by 2023. Experts cite possible factors like diet, obesity, and environmental exposures and stress the role of colonoscopy screening—ACS recommends starting regular screenings at age 45—in preventing deaths, though uptake in ages 45–49 remains a key target for reducing early-onset CRC.
Federal guidelines now allow women aged 30-65 at average risk to choose self-administered HPV tests every five years for cervical cancer screening, providing a more private and accessible option alongside traditional Pap smears, with the aim of increasing screening rates and early detection.
The article discusses the pros and cons of PSA testing for prostate cancer, emphasizing that while it can produce false positives leading to unnecessary procedures, careful testing and risk assessment can help identify high-risk cases and save lives. The author supports PSA screening for men aged 50-70 and suggests that digital rectal exams add little value and often result in false positives, but individual discussions with doctors are important.
Dr. Keith Roach discusses the importance of PSA tests and DREs in prostate cancer screening, emphasizing that PSA testing remains valuable for men aged 50-70 despite some controversy over false positives, and that DREs add limited diagnostic value but are still part of the screening conversation.
World-leading experts have proposed updated guidelines for prostate cancer screening, suggesting reduced frequency for some men from two to five years. The American Urological Association recommends screenings every two to four years, including an internal exam and a PSA blood test. Prostate cancer is common in men over 50, but determining who should be screened and how often is complex and varies based on age, race, and family history. New guidelines based on PSA levels suggest low-risk men should be screened every five years, while medium-risk should be screened every two years. Additional testing and treatment may be prescribed for high-risk individuals. Studies indicate that PSA testing alone has limited impact on reducing prostate cancer mortality, prompting the exploration of biomarker panels for more effective screening. Prostate cancer, often asymptomatic in its early stages, can be challenging to detect and is associated with various risk factors. Treatment options include prostatectomy for localized cancer.
A study from the CDC reveals that factors such as social isolation, food insecurity, job loss, and transportation issues are contributing to about a quarter of women aged 50 to 74 not being up to date on routine mammograms. The study emphasizes the importance of addressing women's health-related social needs to improve mammogram participation, as it found that women with more health-related social needs were less likely to have received a mammogram in the previous two years. The study also highlights the disproportionate impact of breast cancer on Black women and the potential of mammography screenings to reduce cancer deaths. New draft guidelines recommend women start regular mammograms at 40 and continue through age 74.
Colorectal cancer is now the leading cause of cancer death in men under 50 and the second leading cause in women under 50, with cases steadily rising by 2% per year since the mid-1990s. Factors such as genetic mutations, diet changes, decreased physical activity, imbalances in the gut microbiome, and exposure to toxic chemicals may contribute to the increase. Patients are being diagnosed at advanced stages, emphasizing the importance of awareness and early screening, with the new recommended age for colonoscopy screening being 45. Symptoms to watch out for include blood in the stool, abdominal pain, unexplained weight loss, and changes in bowel habits.
The incidence of colorectal cancer in younger adults is on the rise in Colorado, with 452 people under 55 diagnosed in 2020, a 23% increase from a decade earlier. Despite a drop in death rates for people over 55, deaths from colorectal cancer among younger individuals have been increasing. Delayed detection during the pandemic may be a factor, but the rise cannot be fully explained by population growth. Screening and early detection through colonoscopies are crucial in preventing deaths from colorectal cancer, and lifestyle factors such as diet and alcohol consumption may contribute to the increased risk in younger adults. Advocates are pushing for insurance coverage for biomarker testing to improve cancer treatment.
Colorectal cancer, the third most common cancer worldwide, is the top cause of cancer death in men under 50 and second only to breast cancer for women in the same age group. New guidelines recommend screening at age 45, as rates of diagnosis in people under 50 have increased. People of color and those with family history are disproportionately impacted, emphasizing the importance of timely diagnosis, appropriate treatment, and regular follow-up care for improving survival rates and quality of life.